Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GC33 + sorafenib
- Development stage
- Phase 1
- Lead developer
- Chugai Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
GC33 + sorafenib is a combination therapy of **codrituzumab** (also known as GC33 or RO5137382), a recombinant, fully humanized monoclonal antibody targeting glypican-3 (GPC3), and **sorafenib**, a small molecule multikinase inhibitor. GC33 binds to GPC3, an oncofetal protein overexpressed in hepatocellular carcinoma (HCC), mediating antibody-dependent cellular cytotoxicity (ADCC), while sorafenib targets multiple kinases involved in tumor cell proliferation and angiogenesis (including VEGFR2, PDGFR, RAF kinases). The combination has been evaluated and shown to have an additive antitumor effect in preclinical models and clinical studies in patients with advanced HCC. Clinical trials report that the regimen is generally tolerable, with expected toxicities, but did not achieve superior efficacy compared to single-agent sorafenib[1][2].
- Other names
- codrituzumab + sorafenib
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)GPC3 (Glypican-3)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on GC33 + sorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GC33 + sorafenib.